SignalX Weekly2026 W43Oct 19 to Oct 23, 2026

Insider sales fell to $548M, the lowest week of 2026

Meta will give holders a new non-voting Class C share for each share they own, Salesforce agreed to buy Braze, and Abbott plans to spin off its Nutrition business. Insider selling hit its lowest week of the year during a heavy earnings week.

Published Data as of

Officer and director open-market sales, by week

Form 4s filed Monday to Friday, non-derivative shares, code S

$2.63B
Show data
Officer and director open-market sales, by week
Week ofValue
Aug 24, 2026$2.63B
Aug 31, 2026$2.01B
Sep 7, 2026$1.64B
Sep 14, 2026$2.19B
Sep 21, 2026$2.02B
Sep 28, 2026$1.04B
Oct 5, 2026$1.28B
Oct 12, 2026$857M
Oct 19, 2026$548M
8-Ks filed
1,201
+44% vs 832 prior week
High-importance 8-Ks
198
+15% vs 172 prior week
SignalX score 3 or higher out of 4
Insider open-market buys
$36.5M
−71% vs $128M prior week
Insider open-market sales
$548M
−36% vs $857M prior week

What were the biggest filings this week?

Ranked by company size, importance and dollar value

  1. 1
    Meta PlatformsMETAShare structure

    The board created a non-voting Class C stock and declared a one-time dividend of one Class C share for each Class A and Class B share, payable after a restated charter takes effect on January 19, 2027. Under a Founder Alignment Agreement, 20% of the Class C shares Mark Zuckerberg's group receives can be sold freely; the other 80% can generally be sold only alongside a sale of voting shares or a Class B conversion.

    8-K Item 1.01, 2.02, 8.01 · Oct 210001628280-26-066700
  2. 2
    SalesforceCRM+BrazeBRZEAcquisition

    Salesforce agreed to acquire Braze for about $5.66B in enterprise value. Braze Class A holders will receive $47.50 a share in cash, and Braze's board approved the merger agreement unanimously.

    8-K Item 1.01, 8.01 · Oct 200000950103-26-0158508-K Item 7.01 · Oct 200001193125-26-425881
  3. 3
    AbbottABTSpin-off

    Abbott plans to separate its Nutrition business (Similac, PediaSure, Pedialyte, Glucerna, Ensure; about $8.5B in annual sales) into an independent public company through a tax-free distribution to shareholders. The separation is expected to be completed by the end of 2027.

    8-K Item 8.01 · Oct 210001104659-26-117587
  4. 4
    Prudential FinancialPRUDivestiture

    Prudential agreed to sell Prudential of Brazil and Prudential of Mexico to the CNP Assurances group for about $4.025B in cash. Closing is expected in the second half of 2027, pending regulatory approvals.

    8-K Item 7.01, 8.01 · Oct 200001193125-26-425703
  5. 5
    Rapport TherapeuticsRAPPInsider cluster

    A day after the company said its Phase 2 trial of RAP-219 in bipolar mania met its primary endpoint (p=0.045), the CFO and five directors bought shares on the open market from October 21 to 23: about $1.66M at an average $26.99. Phase 3 trials are expected to begin in the second half of 2027.

    8-K Item 7.01, 8.01 · Oct 200001193125-26-425647Form 4 filings, trades Oct 21 to 23

What did insiders buy and sell?

Officer and director sales fell to $548M, down from $857M the week before and the lowest week of 2026. Buys dropped to $36.5M, the lowest since the week of July 13. It was a heavy earnings week (370 8-Ks carried Item 2.02), and many companies close their insider trading windows around earnings releases.

Open-market buys, by week

Officers and directors, Form 4s filed each week

$430M
Show data
Open-market buys, by week
Week ofValue
Aug 3, 2026$53.8M
Aug 10, 2026$191M
Aug 17, 2026$430M
Aug 24, 2026$112M
Aug 31, 2026$129M
Sep 7, 2026$130M
Sep 14, 2026$97.9M
Sep 21, 2026$225M
Sep 28, 2026$283M
Oct 5, 2026$166M
Oct 12, 2026$128M
Oct 19, 2026$36.5M

Open-market sales, by week

Same weeks, different scale from buys

$4.15B
Show data
Open-market sales, by week
Week ofValue
Aug 3, 2026$2.98B
Aug 10, 2026$4.15B
Aug 17, 2026$3.90B
Aug 24, 2026$2.63B
Aug 31, 2026$2.01B
Sep 7, 2026$1.64B
Sep 14, 2026$2.19B
Sep 21, 2026$2.02B
Sep 28, 2026$1.04B
Oct 5, 2026$1.28B
Oct 12, 2026$857M
Oct 19, 2026$548M
Notable buys
CompanyWhoTrade datesValueAvg price
Applied DigitalAPLDCEO and President
President Jason Zhang $5.66M
10/16$6.7M$18.73
Rapport TherapeuticsRAPPCFO and 5 directors
Director Steven Paul $974K
10/21 to 10/23$1.7M$26.99
FB FinancialFBKOrrin Ingram, director10/20$1.5M$52.88
Largest CEO and CFO sales
CompanyWhoTrade datesValueAvg price
TravelersTRVAlan Schnitzer, CEO10/21$35.3M$396.77
UiPathPATHDaniel Dines, CEO
2.5 million shares
10/15 to 10/16$33.1M$13.23
United TherapeuticsUTHRMartine Rothblatt, CEO10/16 to 10/22$26.4M$555.06
CrowdStrikeCRWDGeorge Kurtz, CEO10/15 to 10/22$14.1M$234.30
Travere TherapeuticsTVTXEric Dube, CEO10/15$13.1M$53.82
WayfairWNiraj Shah, CEO10/15$13.0M$111.25

Large executive sales are often made under prearranged 10b5-1 plans, so they say less than buys; each Form 4 footnote says whether a plan was used. Left out of the buy table: one-day purchases at a single price that can be offering allocations (Iambic Therapeutics, IAM, $11.5M at $16.00; City Therapeutics, CTY, $3.06M at $18.00; Rent the Runway, RENT, $2.2M at $3.55), interval and private funds, and prices under $1.

What did the 8-Ks say?

8-Ks rose to 1,201 from 832, the most since the week of August 10, as third-quarter reporting picked up: Item 2.02 (earnings release) was the most common item, on 370 filings. One 8-K can carry several items, so the counts add up to more than 1,201.

8-K items filed this weekOne 8-K can carry several items
  • 2.02Earnings release370
  • 7.01Reg FD disclosure355
  • 8.01Other events324
  • 5.02Officer or director change186
  • 1.01Material agreement170
  • 3.02Unregistered stock sale73
  • 5.03Bylaw amendment49
  • 2.03New debt43
  • 5.07Shareholder vote38
  • 3.01Listing deficiency26
  • 2.01Deal completed19

Deals and closings

  • AESEU (Oct 15) and New York PSC (Oct 19) approvals for the merger that will leave AES owned by Global Infrastructure Management and EQT Infrastructure VI vehicles; other approvals remain8-K Item 8.01 · Oct 190001140361-26-040117
  • TTM TechnologiesTTMIAgreed to buy MKS's Ophir Optics business for about $650M in cash8-K Item 8.01 · Oct 190001193125-26-424707
  • NordsonNDSNCompleted the purchase of Swiss sensor maker Contrinex at an enterprise value of about $168M8-K Item 7.01, 8.01 · Oct 230000072331-26-000063

Red flags

  • Getty ImagesGETYFiled a prepackaged Chapter 11 on October 21; if the plan is confirmed, existing common stock is cancelled and holders receive nothing8-K Item 1.03, 2.04, 7.01 · Oct 210001213900-26-111193
  • EyePointEYPTAfter LUCIA Phase 3 topline data, will end its wet AMD Phase 3 trials early and cut about 53% of staff (about $9M in charges) to focus on DME8-K Item 2.02, 2.05, 8.01 · Oct 190001193125-26-424755
  • eBayEBAYCutting about 9% of its global workforce, with $130M to $150M of pre-tax charges mostly in Q4; separately expects Q3 results above guidance8-K Item 2.02, 2.05 · Oct 220001065088-26-000205

Leadership changes

  • Expand EnergyEXEDaniel Brown, most recently CEO of Chord Energy, becomes President and CEO, expected October 268-K Item 5.02, 7.01 · Oct 190001104659-26-116739
  • Comfort Systems USAFIXCFO William George retires after the 2026 10-K is filed; Chief Accounting Officer Julie Shaeff succeeds him8-K Item 5.02, 7.01 · Oct 220001104659-26-118149
  • MedtronicMDTMichael Marinaro named President effective October 14; Geoffrey Martha stays Chairman and CEO. The same 8-K said the MiniMed separation is complete8-K Item 5.02, 5.07, 7.01 · Oct 190001628280-26-066291

Trials and financing

  • Disc MedicineIRONPhase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria met all primary and secondary endpoints8-K Item 7.01, 8.01 · Oct 190001193125-26-424649
  • Kimberly-ClarkKMBPriced $4.9B of senior notes in five tranches (5.10% to 5.80%, due 2028 to 2036) to help fund the cash part of the Kenvue acquisition, expected to close in Q4 20268-K Item 8.01 · Oct 200001104659-26-117036

Activists and funds

13D stakes

No 13D from a tracked filer this week; the most recent one was filed on October 15.

13F holdings

Third-quarter 13Fs are due Monday, November 16, because November 14 falls on a Saturday. None were filed this week; last quarter 79 arrived in the deadline week alone (August 10 to 14).

Frequently asked questions

What is the SignalX Weekly?

A weekly summary of what U.S. companies filed with the SEC: 8-K events, Form 4 insider trades, 13D stakes and 13F deadlines. SignalX collects the filings from EDGAR, counts them, and links every highlighted item to its source filing.

How are the insider totals counted?

Open-market purchases (code P) and sales (code S) of non-derivative shares by officers and directors, from Form 4s filed Monday to Friday. Duplicate joint filings are removed and prices above $20,000 a share are dropped as data errors.

Why do insider trades drop in earnings season?

Many companies close the trading window for officers and directors in the weeks before and right after an earnings release. In this issue's week, 370 8-Ks carried Item 2.02 (earnings release), and officer and director sales were the lowest of any week in 2026.

Is this investment advice?

No. It reports what companies and insiders disclosed in public filings. Check the original filing before acting on anything here.

Data and method

Source: SEC EDGAR filings collected and classified by SignalX. 8-Ks filed Oct 19 to Oct 25; insider figures cover officer and director open-market purchases (P) and sales (S) of non-derivative shares on Form 4s filed Oct 19 to Oct 23, with joint-filing duplicates and prices above $20,000 a share removed. Importance scores (0 to 4) and event types come from SignalX's classification model. Data as of Oct 24, 2026.

SignalX Weekly summarizes public SEC filings for research. It is not investment advice. Figures are as of the data date above and can change if a filing is amended.

Follow these filings as they land

The insider screener and company pages update as new filings arrive on EDGAR.